Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts di...
Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth
About this item
Full title
Author / Creator
Peter, B , Winter, G E , Blatt, K , Bennett, K L , Stefanzl, G , Rix, U , Eisenwort, G , Hadzijusufovic, E , Gridling, M , Dutreix, C , Hoermann, G , Schwaab, J , Radia, D , Roesel, J , Manley, P W , Reiter, A , Superti-Furga, G and Valent, P
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Proteomic-based drug testing is an emerging approach to establish the clinical value and anti-neoplastic potential of multikinase inhibitors. The multikinase inhibitor midostaurin (PKC412) is a promising new agent used to treat patients with advanced systemic mastocytosis (SM). We examined the target interaction profiles and the mast cell (MC)-targ...
Alternative Titles
Full title
Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4896384
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4896384
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/leu.2015.242
